Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | MMP2 | P08253 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17039332 | 0.81 | CA12 (0.36) | CYP1A2CYP3A4METAP1CA12CA1 | |
| SCHEMBL17039330 | 0.77 | CA12 (0.32) | CYP1A2CYP3A4METAP1CA12CA1 | |
| SCHEMBL19229693 | 0.75 | METAP1 (0.35) | CYP1A2CYP3A4METAP1CA12CA1 | |
| SCHEMBL21276551 | 0.74 | — | — | |
| SCHEMBL17036737 | 0.73 | MMP1 (0.36) | MMP2MMP1 | |
| SCHEMBL19229690 | 0.71 | METAP1 (0.32) | METAP1 | |
| SCHEMBL20730704 | 0.69 | METAP1 (0.30) | METAP1 | |
| SCHEMBL5509358 | 0.68 | CA12 (0.39) | CYP1A2CYP3A4METAP1CA12CA1 | |
| SCHEMBL17342201 | 0.68 | CA2 (0.45) | CYP1A2METAP1CA12CA1CA2 | |
| SCHEMBL5670794 | 0.67 | CA12 (0.41) | METAP1CA12CA1CA2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550140-B2 | Ether compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190048033-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550140-B2 | Ether compounds for treatment of complement mediated disorders | TFPI, CFD, C9 | CYP1A2 2820/4885CYP3A4 2611/4885METAP1 2446/4885 |
| US-20190048033-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, C9 | CYP1A2 2820/4885CYP3A4 2611/4885METAP1 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.